No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Tyber Medical Reaches Agreement to Acquire CatapultMD

Purchase of contract manufacturer's assets will double Tyber's manufacturing footprint to 100,000-square feet

Editor: What To Know

  • “On behalf of the CatapultMD team, we are pleased that Tyber Medical will be the new owner of this business, enabling it to further flourish for the benefit of our customers and beyond,”.
  • As Tyber Medical continues to expand its customer base and product portfolio, which includes private label orthopedic implants for the trauma, extremity, and spine markets, it will now double its manufacturing capacity upon purchasing all the assets of CatapultMD, based in Bonita Springs, Florida.
  • Len Zaiser is well-known through the founding of Structure Medical and well-respected for his unique engineering talent and creativity in using state-of-the-art precision machine tools and equipment to ensure that the most complicated designs meet the highest quality standards.

Tyber Medical, since its founding in 2012, has experienced record growth with its continually expanding product portfolio.

In support of its rapid growth, the company implemented a vertical integration strategy, in 2019, that included a large-scale expansion of its headquarters located in the Lehigh Valley in Pennsylvania.

As Tyber Medical continues to expand its customer base and product portfolio, which includes private label orthopedic implants for the trauma, extremity, and spine markets, it will now double its manufacturing capacity upon purchasing all the assets of CatapultMD, based in Bonita Springs, Florida.

Once the acquisition is complete, Tyber Medical will own and operate a combined 100,000-square feet of manufacturing space between its Pennsylvania headquarters and Florida-based facilities. The acquisition will expand Tyber Medical’s machining footprint to include over 40 CNC Swiss machines and 10, 5-axis CNC mills for manufacturing plates, screws, spinal implants, and instrumentation used in orthopedic surgery.

With the receipt of two U.S. Food and Drug Administration (FDA) 510(k) clearances for its anatomical plating systems in the last year, Tyber Medical now offers its most comprehensive portfolio of products, since its founding in 2012. “We’ve been on a significant growth trajectory fueled by our expert research and development team, outstanding engineering capability, and our recent FDA clearances,” said Tyber Medical Chief Executive Officer Jeff Tyber. “Our acquisition of CatapultMD’s top-of-the-line CNC automation and inspection capabilities seamlessly aligns with our strict MDSAP and ISO 13485 quality standards and enables us to meet and exceed our growing demand by instantaneously doubling our internal manufacturing and processing capacity.”

The CatapultMD transaction is expected to add up to 24 team members to Tyber’s current workforce of 120, including the co-founders of CatapultMD, Len and Oliver Zaiser. Len Zaiser is well-known through the founding of Structure Medical and well-respected for his unique engineering talent and creativity in using state-of-the-art precision machine tools and equipment to ensure that the most complicated designs meet the highest quality standards.

“On behalf of the CatapultMD team, we are pleased that Tyber Medical will be the new owner of this business, enabling it to further flourish for the benefit of our customers and beyond,” said CatapultMD President and founder Oliver Zaiser.

The acquisition gives Tyber Medical access to the diverse customers that CatapultMD currently serves. “We are very excited to serve these medical device companies and welcome them into our Tyber Medical customer family,” said Tyber. “Our business is based on filling gaps in our customers’ product portfolios by bringing FDA-cleared, MDR-compliant, and CE-approved medical devices to market for them in less than 12 months. Our acquisition of CatapultMD will help us ensure that our integrated supply chain will continue to meet our critical speed to market metric.”

The transaction is expected to close before the end of the year.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy